Menu
← Oncology Approval Tracker
FDA DECISION ·
Braftovi + cetuximab + chemotherapy
encorafenib with cetuximab and fluorouracil-based chemotherapy · Array BioPharma / Pfizer
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with metastatic colorectal cancer and a BRAF V600E mutation identified by an FDA-authorized test.
LAMPGEN ANALYSIS
Why it matters
The decision converts accelerated approval and supports a fluorouracil-based chemotherapy backbone. BREAKWATER evaluated the targeted combination in treatment-naïve metastatic disease.
What research teams should watch
Confirm the exact BRAF alteration and chemotherapy backbone. Trial teams should reassess comparator relevance where the first-line treatment landscape changes.
Related study operations checklist
See the staffing responsibilities, timing, and handoff questions for this study setting.
Molecularly selected metastatic diseasePRIMARY RECORDS